Chongkundang (001630) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Chongkundang stock KRW 108,000, price KRW 36,000, upside +200.0%, quality 48 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 35,050 KRW – 98,095 KRW · fair‑value band 65,081 KRW – 144,385 KRW · the 36,000 KRW price screens below the 108,000 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Chongkundang in your weekly email
Every Wednesday you see whether Chongkundang is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. Chong Kun Dang Holdings Corp. was founded in 1941 and is based in Seoul, South Korea.
Stock analysis
Chongkundang (001630) currently trades at 36,000 KRW, while our model-based Fair Value estimate is 108,000 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 138,046 KRW per share, and 24 of the 26 models we run sit above the 36,000 KRW price.
Bear case: the Dividend Discount group reads lowest at 20,330 KRW, and 2 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 65,081 KRW (bear) to 144,385 KRW (bull), the price of 36,000 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Chongkundang reported revenue of 959B KRW in FY2025 versus 926B KRW in FY2021, a compound +0.9%/yr. Reported net income was 40.4B KRW in FY2025, compounding +26.1%/yr from FY2021.
Key figures
Market cap 171B KRW (≈ $127M) Micro · P/E ratio 3.2 · P/S ratio 0.24 · EPS (TTM) 11,275 KRW · Dividend yield 3.9% · Net margin 5.6% · Return on equity 7.9% · Return on assets (EBIT) 1.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, 001630 screens cheaper than that median.
Fair Value models
Bear65,081 KRWFair Value 108,000 KRWBull144,385 KRW
Price 36,000 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (8,468 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.48/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2020 (pandemic). Over 10 years: +15.8% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.1%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.1% vs 3.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +22.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)7.9% · Above median
Return on assets3.3% · Below median
Net margin (12 months)7.5% · Below median
Operating margin (12 months)2.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)3.7% · Below median
Dividend yield (12 months)3.9% · Top 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)3.2× · Cheapest 25%
P/B0.27× · Cheapest 25%
P/S (12 months)0.24× · Cheapest 25%
Price / free cash flow (fiscal year)12.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Chongkundang Fair Value". https://www.fairvalue-calculator.com/stock/001630
Frequently asked questions
Is Chongkundang (001630) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 108,000 KRW versus a price of 36,000 KRW, about +200% upside (undervalued).
What is the fair value of 001630?
Our model-based fair value for Chongkundang is 108,000 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 36,000 KRW.
What is the quality score of 001630?
Chongkundang has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chongkundang (001630)?
Our model-based price target is the fair value of 108,000 KRW (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 65,081 KRW, optimistic scenario 144,385 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Chongkundang stock forecast for 2026?
Our models put fair value at 108,000 KRW, about +200% upside versus a price of 36,000 KRW (undervalued). Cautious scenario 65,081 KRW, optimistic scenario 144,385 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Chongkundang (001630)?
Chongkundang reported trailing-twelve-month revenue of about 962B KRW (latest available figure, as of Nov 8, 2026).
Does Chongkundang pay a dividend?
Chongkundang currently shows a dividend yield of 3.89% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Chongkundang (001630) and when is the ex-dividend date?
Chongkundang pays a dividend of 1,400 KRW per share a year, a dividend yield of 3.9%. The last ex-dividend date was Mar 30, 2026. The payout ratio is 12.4% of earnings. Free cash flow covers the dividend 2.76 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Chongkundang (001630)?
For today's price to be fair in a discounted-cash-flow model, Chongkundang would have to grow free cash flow by +24.7 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.3 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 001630 use?
Our models discount Chongkundang at 11.6 %: a base by market capitalisation (micro), damped by beta 0.52, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Chongkundang that is +24.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Chongkundang (001630) delivered so far?
Over the past 5 years revenue at Chongkundang grew +2.3 % a year. The price currently implies free-cash-flow growth of +24.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Chongkundang (001630) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Chongkundang (+24.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Chongkundang (001630)?
The free-cash-flow yield on the price is 10.74 %: that much free cash flow Chongkundang produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Chongkundang (001630)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chongkundang it is 108,000 KRW per share (as of Nov 8, 2026), against a price of 36,000 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Chongkundang stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 001630 trades below its calculated fair value: price 36,000 KRW, fair value 108,000 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 001630?
No. The price is what the market pays today (36,000 KRW); the fair value is what the company's own numbers justify (108,000 KRW). For Chongkundang the two are 72,000 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Chongkundang worth?
The market values Chongkundang at about 171B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 36,000 KRW; our models calculate a fair value of 108,000 KRW per share.
What do the bullish and bearish scenarios say about 001630?
Our models span a range for Chongkundang: cautious scenario 65,081 KRW, base 108,000 KRW, optimistic 144,385 KRW per share (as of Nov 8, 2026, price 36,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 001630?
Chongkundang trades at a price-to-earnings ratio of 3.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 108,000 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 9.6. Other multiples: P/B 0.3, P/S 0.2, EV/EBITDA 2.0.
How solid is the balance sheet of Chongkundang (001630)?
Balance-sheet figures for Chongkundang (as of Nov 8, 2026): return on equity 7.9%, debt of 0.09 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 001630 from its 52-week high?
Chongkundang trades at 36,000 KRW, about 31% below its 52-week high of 52,192 KRW and 3% above the low of 35,050 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 108,000 KRW is for.
Which stocks are comparable to Chongkundang?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chongkundang stock attractive at the current price?
The data as of Nov 8, 2026: price 36,000 KRW, calculated fair value 108,000 KRW (+200%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 001630 calculated?
We run Chongkundang through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 108,000 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Chongkundang currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chongkundang (001630)?
The closing price on Nov 9, 2026 was 36,000 KRW. Our model-based fair value is 108,000 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chongkundang right now?
The large discount to fair value meets weak quality (48/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (65,081 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (65,081 KRW to 144,385 KRW) leaves room in how you read the outcome.
Key figures of Chongkundang
How large is the market capitalisation of Chongkundang (001630)?
The market capitalisation of Chongkundang is 171B KRW (≈ $127M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chongkundang (001630)?
The price-to-sales ratio of Chongkundang is 0.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chongkundang (001630)?
Earnings per share at Chongkundang are 11,275 KRW (price ÷ EPS = P/E 3.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chongkundang (001630)?
The dividend yield of Chongkundang is 3.9% (payout 12.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chongkundang (001630)?
The net margin of Chongkundang is 5.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chongkundang (001630)?
The return on equity (ROE) of Chongkundang is 7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chongkundang (001630)?
On an EBIT basis the return on assets of Chongkundang is 1.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chongkundang (001630)?
The operating margin of Chongkundang is 2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chongkundang (001630)?
Revenue at Chongkundang is growing +3.7% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chongkundang (001630)?
Earnings per share at Chongkundang are growing +52.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Chongkundang (001630) carry?
The net debt of Chongkundang is 456B KRW (fiscal year 2025, ≈ 24.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Chongkundang in the live analysis
One click puts Chongkundang on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026